Cited by 378Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCancer-related cognitive impairment studies

Neuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future

Open access
Geda, Yonas E., Schneider, Lon S., Gitlin, Laura N., Miller, David S., Smith, Gwenn S., Bell, Joanne, Evans, Jovier, Lee, Michael +24 more·2013·Alzheimer's & Dementia

Abstract

Neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) are widespread and disabling. This has been known since Dr. Alois Alzheimer's first case, Frau Auguste D., presented with emotional distress and delusions of infidelity/excessive jealousy, followed by cognitive symptoms. Being cognizant of this, in 2010 the Alzheimer's Association convened a research roundtable on the topic of NPS in AD. A major outcome of the roundtable was the founding of a Professional Interest Area (PIA) within the International Society to Advance Alzheimer's Research and Treatment (ISTAART). The NPS‐PIA has prepared a series of documents that are intended to summarize the literature and provide more detailed specific recommendations for NPS research. This overview paper is the first of these living documents that will be updated periodically as the science advances. The overview is followed by syndrome‐specific synthetic reviews and recommendations prepared by NPS‐PIA workgroups on depression, apathy, sleep, agitation, and psychosis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2012.12.001

Cites

82 of 82 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Mild depressive symptoms in later life might be a prodrome of neurodegenerative diseases, where synaptic density decrease is increasingly described.

    “Mild depressive symptoms in later life might be a prodrome of neurodegenerative diseases [52], where synaptic density decrease is increasingly described [53].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 3

  1. [34]Lyketsos CG Sheppard JM Steinberg M Tschanz JA Norton MC Steffens DC Neuropsychiatric disturbance in Alzheimer’s disease clusters into three groups: the Cache County study. [see comments.] Int J Geriatr Psychiatry 2001 16 1043 1053 11746650
  2. [48]Benarroch EE Basic Neurosciences with Clinical Applications 2006 Butterworth Heinemann/Elsevier Philadelphia
  3. [64]Jorm A van Duijn C Chandra V Fratiglioni L Graves A Heyman A Psychiartric history and related exposures as risk factors for Alzheimer’s disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group Int J Epidemiol 1991 20 S43 S47 1917269

Cited by

Sorted by citations

Authors
Geda, Y. E., Schneider, L. S., Gitlin, L. N., Miller, D. S., Smith, G. S., Bell, J., Evans, J., Lee, M., Porsteinsson, A., Lanctôt, K. L., Rosenberg, P. B., Sultzer, D. L., Francis, P. T., Brodaty, H., Padala, P. P., Onyike, C. U., Ortiz, L. A., Ancoli‐Israel, S., Bliwise, D. L., Martin, J. L., Vitiello, M. V., Yaffe, K., Zee, P. C., Herrmann, N., Sweet, R. A., Ballard, C., Khin, N. A., Alfaro, C., Murray, P. S., Schultz, S., Lyketsos, C. G., & ISTAART, N. S. P. I. A. O.
Affiliations
  • Mayo Clinic (US)
  • University of Southern California (US)
  • Johns Hopkins University (US)
  • Bracket Wayne PA USA
  • Pfizer (United States) (US)
  • National Institute of Mental Health (US)
  • University of Minnesota (US)
  • University of Rochester Medicine (US)
  • University of Toronto (CA)
  • University of California, Los Angeles (US)
  • King's College London (GB)
  • UNSW Sydney (AU)
  • Geriatric Research Education and Clinical Center Central Arkansas Veterans Healthcare System Little Rock AR USA
  • Centro de Investigación Biomédica en Red de Salud Mental CIBERSAM Madrid Spain
  • University of California San Diego (US)
  • Emory University (US)
  • University of Washington (US)
  • University of California, San Francisco (US)
  • Northwestern University (US)
  • Sunnybrook Research Institute (CA)
  • University of Pittsburgh (US)
  • Alzheimer's Society (GB)
  • United States Food and Drug Administration (US)
  • University of Iowa (US)
Corresponding author
Lyketsos, Constantine G.
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2013-04-05
Volume
9
Issue
5
Pages
602-608
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W1999233676
Cited by
378
References
82
Citations by year
2026: 15 · 2025: 18 · 2024: 29 · 2023: 32 · 2022: 23 · 2021: 40 · 2020: 42 · 2019: 36 · 2018: 23 · 2017: 29 · 2016: 27 · 2015: 38 · 2014: 20 · 2013: 4 · 2012: 1
FWCI
4.04
Type
journal article
Language
en
Open access
Locations
  • Alzheimer s & Dementia (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
  • Research Portal (King's College London) (submittedVersion)
Funders
  • National Institute of Mental Health (K01-MH68351, R24-MH074779, RC1-MH090770-01)
  • National Institute on Aging (U01-AG006786)
  • National Center for Research Resources (RR024150)
  • Robert Wood Johnson Foundation
  • Baxter International
  • Johnson and Johnson
  • Novartis
  • Pfizer
  • Alzheimer's Association (IIRG-07-28686)
  • GlaxoSmithKline
  • Eisai
  • AstraZeneca
  • Eli Lilly and Company
  • NFL Foundation
  • Elan
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cancer-related cognitive impairment studies
Keywords
neuropsychiatric symptoms, Alzheimer's disease
MeSH terms
Alzheimer Disease, Mental Disorders, Humans

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review